Genetically Engineered Featherless Chickens - Prezi
Recently I read an article about KFC no longer being able to call themselves “Kentucky Fried Chicken” because they don’t actually use chicken in their products, but instead use genetically engineered chickens that looks like this:
The two constructs were transfected into DT40-ASF cells, a genetically engineered chicken B-cell line in which the endogenous chicken ASF/SF2 has been disrupted and replaced by HA-tagged human ASF/SF2 controlled by a tetracycline-repressible promoter as the only source of ASF/SF2 (, ). Two stable cell lines (DT40-ASF-BPV-1-1 and -2) expressing the respective BPV-1 late minigenes were obtained. In these cell lines, the viral RNAs expressed from the BPV-1 late minigenes were spliced at the proximal 3′ splice site with no detectable unspliced, full-length pre-mRNAs, while selection of the distal 3′ splice site for the viral RNA splicing was minimal, usually below the detection level of a one-time reverse transcription-PCR assay (lanes 2 of Fig. and B) or RNase protection assay (see Fig. , lane 2).
This is a forwarded email alleging that KFC (formerly known as Kentucky Fried Chicken) is trying to increase profits by developing genetically engineered chickens that have more meat, are cheaper to raise, and faster to process. They are variously described as having no heads, no beaks, no legs, and no feathers. That’s why they changed their name to KFC.
KFC denies it and there is no evidence of the genetically engineered chickens described. KFC uses chickens that are born from other chickens in the normal way. KFC did not change it’s name in order to accommodate chickens that are not really chickens.When placed in ultraviolet light, the beaks and feet of these genetically engineered chicken glow neon green, to help researchers tell them apart from the other birds. But glow-in-the-dark features aren't the traits these birds are being breed for, but rather the ability to help fight the spread of avian bird flu.The “Kanuma Chickens” represent the third genetically engineered animal that FDA has approved via its new animal drug authorities. The first such approval was for a goat that produces a human biologic in its milk, which was approved in 2009 (see our post on the Atryn Goats ). The second was the genetically engineered AquAdvantage Salmon, which FDA approved last month for use as a food-producing animal (see our post on the salmon approval ). The Kanuma Chickens are the second CVM approval for an animal engineered to produce a pharmaceutical product, and the first approval of a genetically engineered chicken. The DT40 cell line has been used extensively to better understand the nature of immunoglobulin diversification in chickens, including the mechanism of GC (–). The cell line has also been used to develop chicken antibodies to novel targets using in vitro selection strategies (, ). We have inserted human V gene arrays into the chicken immunoglobulin loci of DT40. In principle, the human V genes in DT40 cells could be diversified in vitro to provide an unselected library of immunoglobulin sequences from which antigen-specific antibodies could be extracted. However, most therapeutic antibodies are derived from immunized animals producing affinity-matured, antigen-specific antibodies. In the current context, we have used DT40 cells to provide in vitro proof of concept that arrays of human-derived immunoglobulin gene sequences can be diversified by chicken B cells. Subsequently, these sequences will be introduced into chickens to provide genetically engineered animals that can be immunized to produce affinity-matured, antigen-specific antibodies with therapeutic potential. Thus, our purpose with DT40 is to determine whether targeted synthetic human V gene arrays can be used as a substrate for genetic diversification in chicken cells in a way that mirrors what is known regarding the native chicken immunoglobulin loci. Affirmative data in the DT40 culture system inspires confidence that the effort required on the arduous path to generating a genetically engineered chicken will be rewarded with a transgenic animal that performs as expected. Without wishing to limit the invention to any theory or mechanism, in some cases it may be advantageous if the organotypic slice is prepared from a genetically engineered mammal. For example, if the organotypic slice is prepared from the brain tissue of a genetically engineered mouse harboring a gene for green fluorescent protein (GFP) linked to a glial cell marker, it would likely be easier to monitor the location, the growth, the development, or the death of the glial cells because the GFP gene would enable the cell to be observed under a fluorescent microscope. Or, if a user wishes to overexpress a gene in the organotypic slice, the organotypic slice may be prepared from the tissue of a genetically engineered mammal that overexpresses that particular gene. Thus, in some embodiments, the organotypic slice is prepared from a genetically engineered mammal, for example, a genetically engineered mouse, a genetically engineered rat, a genetically engineered rabbit, a genetically engineered dog, a genetically engineered primate, a genetically engineered guinea pig, a genetically engineered cat, a genetically engineered hamster, a genetically engineered pig, a genetically engineered chicken, a genetically engineered goat, a genetically engineered horse, or a genetically engineered cow.